Mark Mikinski, MD
Interventional Cardiology · Salina, KSNPI 1467418897
Payments from drug & device makers
Across 680 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Boston Scientific$2K
- Novartis$853
- Pfizer$611
- Merck$558
- AstraZeneca$502
- plus $3K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 269 | $5,857 |
| Boston Scientific | 81 | $1,745 |
| Novartis | 65 | $853 |
| Pfizer | 45 | $611 |
| Merck | 38 | $558 |
| AstraZeneca | 31 | $502 |
| E.r. Squibb & Sons, L.L.C. | 36 | $489 |
| Amgen | 21 | $376 |
| Abiomed | 9 | $310 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $244 |
| Johnson & Johnson | 16 | $243 |
| Boehringer Ingelheim | 10 | $160 |
| Regeneron Healthcare Solutions, Inc. | 8 | $134 |
| Amarin Pharma, Inc. | 5 | $98 |
| Cvrx, Inc. | 2 | $75 |
| Stryker | 2 | $72 |
| Gilead | 3 | $44 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Esperion Therapeutics, Inc. | 2 | $42 |
| Shockwave Medical, Inc | 1 | $40 |
| Bardy Diagnostics, Inc. | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 2 | $35 |
| Kestra Medical Technology Services, Inc. | 2 | $34 |
| Amryt Pharma Holdings Ltd | 2 | $32 |
| Philips North America LLC | 1 | $31 |
| Akcea Therapeutics, Inc. | 1 | $23 |
| Abbott | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Cardiva Medical, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Infobionic, Inc | 1 | $17 |
| Novo Nordisk | 1 | $14 |
| Penumbra, Inc. | 1 | $10 |
How this compares
$12,835 in reported general payments places this provider in the 50th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other interventional cardiology in Salina
- David BattinSalina$30K
- Peter TadrosKansas City$1.3M
- Mark WileyKansas City$1.3M
- Anthony SpaedyKansas City$527K
- Hussam FarhoudWichita$270K
- Prasad GunasekaranKansas City$266K
- Matthew EarnestMerriam$100K
- Kamal GuptaKansas City$79K
- Maheedhar GedelaWichita$54K
- Priyantha RanaweeraManhattan$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.